Takeda Takes Back Dravet, Lennox-Gastaut Candidate From Ovid

Revising the two companies’ 2017 epilepsy collaboration, Takeda will take over Phase III development and commercialization of soticlestat. Ovid gets $196m up front, and it can shift focus.

Female athletes running towards finish line on track field
Ovid will let Takeda take soticlestat to the finish line

Takeda Pharmaceutical Co. Ltd. and Ovid Therapeutics, Inc. said they are revising their 2017 partnership to address severe pediatric epilepsies on 3 March, with a new agreement that gives the Japanese pharma full development and commercial rights to Phase III-ready soticlestat, while Ovid avoids significant R&D spending commitments and monetizes its share of the drug candidate. Takeda plans to launch Phase III trials of soticlestat in Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) during the second quarter of 2021.

[Sidebar#SC098066]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.